Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

Université de Montréal

$50,000.00

Characterisation of the Biomolecular Signature of COVID-19 in Human Adult and Children Blood through Label-free Raman Spectroscopy_x000d_ _x000d_

FY 2020-21

Summary
Currently, we do not know the proportion of asymptomatic COVID-19 carriers because only the most severe cases are tested. In parallel, the virus also appears to be indolent in children. These carriers can have a high viral load and symptoms often only appear within the second week after the disease onset, which highlights the need for a rapid screening tool. The only available tool to screen for infections is PCR tests of swabs that were put in the nose. However, these tests are not meant for mass population as they are costly, require significant quantities of medical materials, and take up 2h to obtain results. Currently, there is an urgent need to develop a robust, label-free (no need of contrast agent) screening technique that allows for rapid diagnosis. To address this need, we propose to develop a novel screening test based on label-free Raman spectroscopy coupled with machine learning technology to study the biomolecular signature of the virus in blood from both children and adults. This work will occur in collaboration with ODS Medical (our industrial partner), which has extensive expertise in the development of Raman spectroscopy for cancer detection. Raman spectroscopy is an emerging optical technique to detect and identify biomolecules. Previously, Raman spectroscopy was used to study the respiratory syncytial virus and changes in blood from patients with Dengue or Malaria fever. We hypothesize that human has a specific signature of COVID-19 and that our novel technique is capable to identify these biomolecular changes in a label-free approach. This project will elucidate the Raman biomolecular signature of blood from human infected with SARS-CoV-2, allowing the development of new methods to characterize biofluids through learning models. As Raman spectroscopy acquisition takes seconds to minutes and is low-cost, its potential for rapid-screening could allow control of virus spread, particularly if there is more than one wave with more mutations.
Program
Alliance Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
555121-2020
Name nom
Dehaes, Mathieu
Department département
Radiologie, radio-oncologie et médecine nucléaire
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Characterisation of the Biomolecular Signature of COVID-19 in Human Adult and Children Blood through Label-free Raman Spectroscopy_x000d_ _x000d_
Keyword
NSERC
Application summary
Currently, we do not know the proportion of asymptomatic COVID-19 carriers because only the most severe cases are tested. In parallel, the virus also appears to be indolent in children. These carriers can have a high viral load and symptoms often only appear within the second week after the disease onset, which highlights the need for a rapid screening tool. The only available tool to screen for infections is PCR tests of swabs that were put in the nose. However, these tests are not meant for mass population as they are costly, require significant quantities of medical materials, and take up 2h to obtain results. Currently, there is an urgent need to develop a robust, label-free (no need of contrast agent) screening technique that allows for rapid diagnosis. To address this need, we propose to develop a novel screening test based on label-free Raman spectroscopy coupled with machine learning technology to study the biomolecular signature of the virus in blood from both children and adults. This work will occur in collaboration with ODS Medical (our industrial partner), which has extensive expertise in the development of Raman spectroscopy for cancer detection. Raman spectroscopy is an emerging optical technique to detect and identify biomolecules. Previously, Raman spectroscopy was used to study the respiratory syncytial virus and changes in blood from patients with Dengue or Malaria fever. We hypothesize that human has a specific signature of COVID-19 and that our novel technique is capable to identify these biomolecular changes in a label-free approach. This project will elucidate the Raman biomolecular signature of blood from human infected with SARS-CoV-2, allowing the development of new methods to characterize biofluids through learning models. As Raman spectroscopy acquisition takes seconds to minutes and is low-cost, its potential for rapid-screening could allow control of virus spread, particularly if there is more than one wave with more mutations.